Pacira BioSciences Presents 104-Week Data on PCRX-201 at ACR Convergence 2024

Pacira BioSciences Unveils Promising Data for PCRX-201 in Osteoarthritis Treatment at ACR Convergence 2024

TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leader in innovative non-opioid pain therapies, is set to present groundbreaking 104-week safety and efficacy data for its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), at the American College of Rheumatology's annual ACR Convergence meeting in Washington, D.C., from November 14–19, 2024.

The presentation, titled "Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the Knee," will be delivered by Dr. Stanley Cohen, a renowned rheumatologist and Co-Medical Director of the Metroplex Clinical Research Center in Dallas, TX, on Sunday, November 17 from 10:30 am – 12:30 pm EST.

PCRX-201 is designed as a locally administered gene therapy that produces interleukin-1 receptor antagonist (IL-1Ra), an anti-inflammatory protein that significantly reduces interleukin-1 (IL-1) signaling, a key factor in osteoarthritis progression. Unlike systemic therapies, PCRX-201 targets the inflammation directly within the joint, potentially reducing pain and slowing structural damage.

In March 2024, PCRX-201 became the first gene therapy candidate for osteoarthritis to receive the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, offering benefits such as intensive guidance on drug development and potential for expedited review. Additionally, it received Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency in May 2023.

About Pacira BioSciences

Pacira BioSciences is at the forefront of delivering innovative non-opioid pain management solutions. The company offers three commercial-stage treatments: EXPAREL® for postsurgical pain, ZILRETTA® for osteoarthritis knee pain, and iovera° for drug-free pain control. Pacira continues to advance PCRX-201, aiming to provide new hope for patients with osteoarthritis and other prevalent diseases.

For more information, visit www.pacira.com.

Investor Contact: Susan Mesco, (973) 451-4030
susan.mesco@pacira.com

Media Contact: Sara Marino, (973) 248-7005
Sara.marino@pacira.com